Placebo adverse events in headache trials: Headache as an adverse event of placebo

Cephalalgia

Volumn 23, Issue 7, 2003, Pages 496-503

  Reuter, Uwe ^a   Del Rio, M Sanchez ^b   Carpay, J A ^c   Boes, C J ^d   Silberstein, S D ^e  

^a HUMBOLDT UNIVERSITY   (Germany)

^b HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^c Afd Neurologie   (Netherlands)

^d MAYO CLINIC   (United States)

^e THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

Adverse events; Migraine; Non steroidal anti inflammatory drugs; Placebo; Triptan

Indexed keywords

ACETAZOLAMIDE; ACETYLSALICYLIC ACID; ALMOTRIPTAN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DICLOFENAC; ELETRIPTAN; ERGOT ALKALOID; IBUPROFEN; LISINOPRIL; MAGNESIUM; NAPROXEN; NARATRIPTAN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; RIZATRIPTAN; SUMATRIPTAN; TOPIRAMATE; VALPROIC ACID; ZOLMITRIPTAN;

ARTICLE; CLINICAL TRIAL; FATIGUE; HEADACHE; HUMAN; MIGRAINE; NAUSEA; PARESTHESIA; PHOTOPHOBIA; PROPHYLAXIS; SLEEP DISORDER; SOMNOLENCE; VERTIGO; VOMITING; XEROSTOMIA;

ADMINISTRATION, INTRANASAL; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DIHYDROERGOCORNINE; HEADACHE; HUMANS; PLACEBOS; RANDOMIZED CONTROLLED TRIALS; SEROTONIN AGONISTS;

EID: 0141614056     PISSN: 03331024     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-2982.2003.00530.x     Document Type: Article

References (84)

1. Beecher HK. The powerful placebo. JAMA 1955;159:1602-6.
2. Hrobjartsson A, Gotzsche PC. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. N Engl J Med 2001; 344:1594-602.
3. Price DD, Milling LS, Kirsch I, Duff A, Montgomery GH, Nicholls SS. An analysis of factors that contribute to the magnitude of placebo analgesia in an experimental paradigm. Pain 1999; 83:147-56.
4. Petrovic P, Kalso E, Petersson KM, Ingvar M. Placebo and opioid analgesia - imaging a shared neuronal network. Science 2002; 295:1737-40.
5. Levine JD, Gordon NC, Fields HL. The mechanism of placebo analgesia. Lancet 1978; 2:654-7.
6. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT (1B/1D) agonists in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001; 358:1668-75.
7. Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs 2000; 60:1259-87.
8. Eisenberg E, Lurie Y, Braker C, Daoud D, Ishay A. Lamotrigine reduces painful diabetic neuropathy: a randomized, controlled study. Neurology 2001; 57:505-9.
9. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgia, and facial pain. Cephalalgia 1988; 8 Suppl 7:1-96.
10. Rasmussen BK. Epidemiology of headache. Cephalalgia 1995; 15:45-68.
11. Bussone G, Manzoni GC, Cortelli P, Roncolato M, Fabbri L, Benassuti C. Efficacy and tolerability of sumatriptan in the treatment of multiple migraine attacks. Neurol Sci 2000; 21:272-8.
12. Savani N. A double-blind placebo-controlled study assessing the efficacy and tolerability of 50 mg sumatriptan tablets in the acute treatment of migraine. Sumatriptan tablets S2CM07 Study Group. Int J Clin Pract 1999; 105 Suppl:7-15.
13. Pfaffenrath V, Cunin G, Sjonell G, Prendergast S. Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine: defining the optimum dose of oral sumatriptan. Headache 1998; 38:184-90.
14. Tfelt-Hansen P, Henry P, Mulder LJ, Scheldewaert RG, Schoenen J, Chazot G. The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine. Lancet 1995; 346:923-6.
15. Cutler N, Mushet GR, Davis R, Clements B. Whitcher L.Oral sumatriptan for the acute treatment of migraine: evaluation of three dosage strengths. Neurology 1995; 45 Suppl 7:5-9.
16. Oral sumatriptan is effective and well tolerated for the acute treatment of migraine, results of a multicenter study. Neurology 1995; 45 Suppl 7:10-4.
17. Nappi G, Sicuteri F, Byrne M, Roncolato M, Zerbini O. Oral sumatriptan compared with placebo in the acute treatment of migraine. J Neurol 1994; 241:138-44.
18. The Oral Sumatriptan and Aspirin plus Metoclopramide Comparative Study Group. A study to compare oral sumatriptan with oral aspirin plus oral metoclopramide in the acute treatment of migraine. Eur Neurol 1992; 32:177-84.
19. Goadsby PJ, Zagami AS, Donnan GA, Symington G, Anthony M, Bladin PF et al. Oral sumatriptan in acute migraine. Lancet 1991; 338:782-3.
20. Tfelt-Hansen P, Teall J, Rodriguez F, Giacovazzo M, Paz J, Malbecq W et al. Oral rizatriptan versus oral sumatriptan: a direct comparative study in the acute treatment of migraine. Rizatriptan 030 Study Group. Headache 1998; 38:748-55.
21. Havanka H, Dahlof C, Pop PH, Diener HC, Winter P, Whitehouse H et al. Efficacy of naratriptan tablets in the acute treatment of migraine: a dose-ranging study. Naratriptan S2wb2004 Study Group. Clin Ther 2000; 22:970-80.
22. Newman L, Mannix LK, Landy S, Silberstein S, Lipton RB, Putnam DG et al. Naratriptan as short-term prophylaxis of menstrually associated migraine: a randomized, double-blind, placebo-controlled study. Headache 2001; 41:248-56.
23. Mathew NT, Asgharnejad M, Peykamian M, Laurenza A. Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, crossover study. The Naratriptan S2wa3003 Study Group. Neurol 1997; 49:1485-90.
24. Klassen A, Elkind A, Asgharnejad M, Webster C, Laurenza A. Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, parallel-group study. Naratriptan S2WA001 Study Group. Headache 1997; 37:640-5.
25. Bomhof M, Paz J, Legg N, Allen C, Vandormael K, Patel K. Comparison of rizatriptan 10 mg vs. naratriptan 2.5 mg in migraine. Eur Neurol 1999; 42:173-9.
26. Cutler NR, Claghorn J, Sramek JJ, Block G, Panebianco D, Cheng H et al. Pilot study of MK-462 in migraine. Cephalalgia 1996; 16:113-6.
27. Goldberg MR, Lee Y, Vyas KP, Slaughter DE, Panebianco D, Ermlich SJ et al. Rizatriptan, a novel 5-HT1B/1D agonist for migraine: single- and multiple-dose tolerability and pharmacokinetics in healthy subjects. J Clin Pharmacol 2000; 40:74-83.
28. Ahrens SP, Farmer MV, Williams DL, Willoughby E, Jiang K, Block GA et al. Efficacy and safety of rizatriptan wafer for the acute treatment of migraine. Rizatriptan Wafer Protocol 049 Study Group. Cephalalgia 1999; 19:525-30.
29. Pascual J, Vega P, Diener HC, Allen C, Vrijens F, Patel K. Comparison of rizatriptan 10 mg vs. zolmitriptan 2.5 mg in the acute treatment of migraine. Rizatriptan-Zolmitriptan Study Group. Cephalalgia 2000; 20:455-61.
30. Kramer MS, Matzura-Wolfe D, Polis A, Getson A, Amaraneni PG, Solbach MP et al. A placebo-controlled cross-over study of rizatriptan in the treatment of multiple migraine attacks. Rizatriptan Multiple Attack Study Group. Neurol 1998; 51:773-81.
31. Teall J, Tuchman M, Cutler N, Gross M, Willoughby E, Smith B. Rizatriptan (MAXALT) for the acute treatment of migraine and migraine recurrence. A placebo-controlled, outpatient study. Rizatriptan 022 Study Group. Headache 1998; 38:281-7.
32. Gijsman H, Kramer MS, Sargent J, Tuchman M, Matzura-Wolfe D, Polis A et al. Double-blind, placebo-controlled, dose-finding study of rizatriptan (MK-462) in the acute treatment of migraine. Cephalalgia 1997; 17:647-51.
33. Visser WH, Terwindt GM, Reines SA, Jiang K, Lines CR, Ferrari MD. Rizatriptan vs sumatriptan in the acute treatment of migraine. A placebo-controlled, dose-ranging study. Dutch/US Rizatriptan Study Group. Arch Neurol 1996; 53:1132-7.
34. Dahlof C, Diener HC, Goadsby PJ, Massiou H, Olesen J, Schoenen J et al. Zolmitriptan, a 5-HT1B/1D receptor agonist for the acute oral treatment of migraine: a multicentre, dose-range finding study. Eur J Neurol 1998; 5:535-43.
35. Solomon GD, Cady RK, Klapper JA, Earl NL, Saper JR, Ramadan NM. Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine. The 042 Clin Trial Study Group. Neurol 1997; 49:1219-25.
36. Rapoport AM, Ramadan NM, Adelman JU, Mathew NT, Elkind AH, Kudrow DB et al. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose range-finding study. The 017 Clin Trial Study Group. Neurol 1997; 49:1210-8.
37. Visser WH, Klein KB, Cox RC, Jones D, Ferrari MD. 311C90, a new central and peripherally acting 5-HT1D receptor agonist in the acute oral treatment of migraine: a double-blind, placebo-controlled, dose-range finding study. Neurology 1996; 46:522-6.
38. Pascual J, Falk RM, Piessens F, Prusinski A, Docekal P et al. Consistent efficacy and tolerability of almotriptan in the acute treatment of multiple migraine attacks: results of a large, randomized, double-blind, placebo-controlled study. Cephalalgia 2000; 20:588-96.
39. Dahlof C, Tfelt-Hansen P, Massiou H, Fazekas A. Dose finding, placebo-controlled study of oral almotriptan in the acute treatment of migraine. Neurology 2001; 57:1811-7.
40. Diener HC, Jansen JP, Reches A, Pascual J, Pitei D, Steiner TJ. Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot (R)) in the acute treatment of migraine, multicentre, randomised, double-blind, placebo-controlled comparison. Eur Neurol 2002; 47:99-10.
41. Goadsby PJ, Ferrari MD, Olesen J, Stovner LJ, Senard JM, Jackson NC et al. Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan. Eletriptan Steering Committee. Neurol 2000; 54:156-63.
42. Gallagher RM. Acute treatment of migraine with dihydroergotamine nasal spray. Dihydroergotamine Working Group. Arch Neurol 1996; 53:1285-91.
43. Dihydroergotamine Nasal Spray Multicenter Investigators. Efficacy, safety, and tolerability of dihydroergotamine nasal spray as monotherapy in the treatment of acute migraine. Headache 1995; 35:177-84.
44. Ziegler D, Ford R, Kriegler J, Gallagher RM, Peroutka S, Hammerstad J et al. Dihydroergotamine nasal spray for the acute treatment of migraine. Neurology 1994; 44:447-53.
45. Diener HC. Efficacy and safety of intravenous acetylsalicylic acid lysinate compared to subcutaneous sumatriptan and parenteral placebo in the acute treatment of migraine. A double-blind, double-dummy, randomized, multicenter, parallel group study. The ASASUMAMIG Study Group. Cephalalgia 1999; 19:581-8.
46. Lange R, Schwarz JA, Hohn M. Acetylsalicylic acid effervescent 1000 mg (Aspirin) in acute migraine attacks; a multicentre, randomized, double-blind, single-dose, placebo-controlled parallel group study. Cephalalgia 2000; 20:663-7.
47. Boureau F, Joubert JM, Lasserre V, Prum B, Delecoeuillerie G. Double-blind comparison of an acetaminophen 400 mg-codeine 25 mg combination versus aspirin 1000 mg and placebo in acute migraine attack. Cephalalgia 1994; 14:156-61.
48. Lipton RB, Stewart WF, Ryan RE Jr, Saper J, Silberstein S, Sheftell F. Efficacy and safety of acetaminophen, aspirin, and caffeine in alleviating migraine headache pain: three double-blind, randomized, placebo-controlled trials. Arch Neurol 1998; 55:210-7.
49. Nebe J, Heier M, Diener HC. Low-dose ibuprofen in self-medication of mild to moderate headache: a comparison with acetylsalicylic acid and placebo. Cephalalgia 1995; 15:531-5.
50. The Diclofenac K/Sumatriptan Migraine Study Group. Acute treatment of migraine attacks: efficacy and safety of a non-steroidal anti-inflammatory drug, diclofenac-potassium, in comparison to oral sumatriptan and placebo. Cephalalgia 1999; 19:232-40.
51. Dahlof C, Bjorkman R. Diclofenac K (50 and 100 mg) and placebo in the acute treatment of migraine. Cephalalgia 1993; 13:117-23.
52. Massiou H, Serrurier D, Lasserre O, Bousser MG. Effectiveness of oral diclofenac in the acute treatment of common migraine attacks: a double-blind study versus placebo. Cephalalgia 1991; 11:59-63.
53. Kellstein DE, Lipton RB, Geetha R, Koronkiewicz K, Evans FT, Stewart WF et al. Evaluation of a novel solubilized formulation of ibuprofen in the treatment of migraine headache: a randomized, double-blind, placebo-controlled, dose-ranging study. Cephalalgia 2000; 20:233-4.
54. Kloster R, Nestvold K, Vilming ST. A double-blind study of ibuprofen versus placebo in the treatment of acute migraine attacks. Cephalalgia 1992; 12:169-71.
55. Andersson PG, Hinge HH, Johansen O, Andersen CU, Lademann A, Gotzsche PC. Double-blind study of naproxen vs placebo in the treatment of acute migraine attacks. Cephalalgia 1989; 9:29-32.
56. Nestvold K, Kloster R, Partinen M, Sulkava R. Treatment of acute migraine attack: naproxen and placebo compared. Cephalalgia 1985; 5:115-9.
57. Diener HC, Foh M, Iaccarino C, Wessely P, Isler H, Strenge H et al. Cyclandelate in the prophylaxis of migraine: a randomized, parallel, double-blind study in comparison with placebo and propranolol. The Study group. Cephalalgia 1996; 16:441-7.
58. Pfaffenrath V, Wessely P, Meyer C, Isler HR, Evers S, Grotemeyer KH et al. Magnesium in the prophylaxis of migraine - a double-blind placebo-controlled study. Cephalalgia 1996; 16:436-40.
59. Peikert A, Wilimzig C, Kohne-Volland R. Prophylaxis of migraine with oral magnesium: results from a prospective, multi-center, placebo-controlled and double-blind randomized study. Cephalalgia 1996; 16:257-63.
60. Pradalier A, Serratrice G, Collard M, Hirsch E, Feve J, Masson M et al. Long-acting propranolol in migraine prophylaxis: results of a double-blind, placebo-controlled study. Cephalalgia 1989; 9:247-53.
61. van de Ven LL, Franke CL, Koehler PJ. Prophylactic treatment of migraine with bisoprolol: a placebo-controlled study. Cephalalgia 1997; 17:596-9.
62. Kaniecki RG. A comparison of divalproex with propranolol and placebo for the prophylaxis of migraine without aura. Arch Neurol 1997; 54:1141-5.
63. Mathew NT, Saper JR, Silberstein SD, Rankin L, Markley HG, Solomon S et al. Migraine prophylaxis with divalproex. Arch Neurol 1995; 52:281-6.
64. Klapper J. Divalproex sodium in migraine prophylaxis: a dose-controlled study. Cephalalgia 1997; 17:103-8.
65. Storey JR, Calder CS, Hart DE, Potter DL. Topiramate in migraine prevention: a double-blind, placebo-controlled study. Headache 2001; 41:968-75.
66. Vahedi K, Taupin P, Djomby R, El-Amrani M, Lutz G, Filipetti V et al. Efficacy and tolerability of acetazolamide in migraine prophylaxis: a randomised placebo-controlled trial. J Neurol 2002; 249:206-11.
67. Schrader H, Stovner LJ, Helde G, Sand T, Bovim G. Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study. BMJ 2001; 322:19-22.
68. Silberstein SD. Migraine symptoms: results of a survey of self-reported migraineurs. Headache 1995; 35:387-96.
69. Weihrauch TR, Gauler TC. Placebo - efficacy and adverse effects in controlled clinical trials. Arzneimittelforschung 1999; 49:385-93.
70. Pollo A, Amanzio M, Arslanian A, Casadio C, Maggi G, Benedetti F. Response expectancies in placebo analgesia and their clinical relevance. Pain 2001; 93:77-84.
71. Kirsch I, Weixel LJ. Double-blind versus deceptive administration of a placebo. Behav Neurosci 1988; 102:319-23.
72. Gracely RH, Dubner R, Deeter WR, Wolskee PJ. Clinicians' expectations influence placebo analgesia. Lancet 1985; 1:43.
73. Lamb GC, Green SS, Heron J. Can physicians warn patients of potential side effects without fear of causing those side effects? Arch Intern Med 1994; 154:2753-6.
74. Myers MG, Cairns JA, Singer J. The consent form as a possible cause of side effects. Clin Pharmacol Ther 1987; 42:250-3.
75. de Craen AJ, Tijssen JG, de Gans J, Kleijnen J. Placebo effect in the acute treatment of migraine: subcutaneous placebos are better than oral placebos. J Neurol 2000; 247:183-8.
76. Haldemann R, Good M, Holsboer-Trachsler E. Epidemiological study of sleep disorders in patients in Swiss general practice. Schweiz Rundsch Med Prax 1996; 85:1656-62.
77. Rasmussen BK, Jensen R, Schroll M, Olesen J. Epidemiology of headache in a general population - a prevalence study. J Clin Epidemiol 1991; 44:1147-57.
78. Dahlof C, Linde M. One-year prevalence of migraine in Sweden: a population-based study in adults. Cephalalgia 2001; 21:664-71.
79. Linet MS, Stewart WF, Celentano DD, Ziegler D, Sprecher M. An epidemiologic study of headache among adolescents and young adults. JAMA 1989; 261:2211-6.
80. Scharff L, Turk DC, Marcus DA. Triggers of headache episodes and coping responses of headache diagnostic groups. Headache 1995; 35:397-403.
81. Voudouris NJ, Peck CL, Coleman G. The role of conditioning and verbal expectancy in the placebo response. Pain 1990; 43:121-8.
82. Bhatia MS. Allergy to tartrazine in psychotropic drugs. J Clin Psychiatry 2000; 6:473-6.
83. American Academy of Pediatrics. 'Inactive' ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. Pediatrics 1997; 99:268-78.
84. Beaudouin E, Kanny G, Lambert H, Fremont S, Moneret-Vautrin DA. Food anaphylaxis following ingestion of carmine. Ann Allergy Asthma Immunol 1995; 74:427-30.